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Prior research has demonstrated that a fear of unwarranted medical malpractice liability 
causes doctors and other healthcare practitioners to engage in self-protective activities, such as 
ordering unnecessary tests or treatments. This paper examines the impact that the liability system 
could have on prescription drug use. It reports on a Harris poll of doctors, pharmacists and 
patients. Situations where patients fail to receive appropriate medications as a direct result of the 
liability system are revealed. It recommends reforms that allow healthcare professionals to know 
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The Adverse Side Effects of Pharmaceutical Litigation              
 
Judyth Pendell  
Introduction 
Healthcare is a public policy issue in which everyone has a very personal stake.  
Individual concerns about whether or not quality care will be available when it is needed 
commonly focus on whether good doctors and hospitals, and the best technology, will be 
accessible and affordable. It probably rarely occurs to anyone that even when the best 
care is within reach it might not be forthcoming because doctors or nurses or pharmacists 
may have concerns about themselves that trump their concerns about their patients.  
Fear of unwarranted malpractice liability claims can create just such a conflict.  In 
2002, Common Good, an organization headed by lawyer and author Philip Howard, 
produced new, compelling evidence that doctors and other healthcare professionals are so 
concerned about unfounded lawsuits that they order unnecessary tests and procedures, 
and sometimes feel constrained from providing the candor and openness that would serve 
the patient’s best interest.   
Building on that work, this paper provides a window into how fear of liability 
could be getting in the way of patients not receiving medications they should have. The 
paper discusses first the dominance of non-meritorious suits and how the liability system 
creates undesirable incentives in the delivery of healthcare generally. It then discusses the 
findings of a Harris poll in which doctors, pharmacists, and patients are interviewed 
about how liability over pharmaceuticals is affecting their behaviors relative to 
prescribing, warning, and compliance with prescriptions.
1 It concludes that the 
randomness and uncertainty of the liability system is creating perverse incentives, 
including deterring pharmaceutical companies from research and development in some 
areas.  
Healthcare professionals and pharmaceutical companies should be able to 
anticipate with some reliability which actions will result in liability being imposed, and 
which actions will provide protection from liability. Healthcare liability should be 
                                                 
   
1 The U.S. Chamber Institute for Legal Reform commissioned Harris Interactive to conduct a study on the 
issue of pharmaceutical product liability litigation.  The study was conducted among three target 
populations: physicians, pharmacists, and patients.  A PowerPoint presentation on “Pharmaceutical 
Liability Study Report on Findings” prepared for the U.S. Chamber Institute for Legal Reform can be 
viewed at http://www.aei-brookings.org/admin/pdffiles/phpgm.pdf.                                                                                                                                     2
reformed to allow for that predictability. Freedom from fear of liability will restore 
patient well-being as the dominant priority.           
 
Background 
The tort system was always meant to affect the conduct of professionals, 
businesses, and organizations. The rationale has been that if those who provide goods and 
services are required to pay for the harm they cause they will be deterred from causing 
harm. The deterrence theory of tort litigation has recently come under intense scrutiny 
and criticism, however, among legal scholars. Priest
2 and Viscusi
3 have conducted 
research that concludes that the tort system does not appear to be making products or the 
environment safer.  Sunstein, Schkade, and Kahneman
4 have questioned whether people 




8 have focused on 
whether the tort system over-deters, whether efforts to protect against liability actually 
create socially undesirable behavior. For example, Garber’s research shows how the tort 
system may be encouraging undesirable behaviors such as avoidance of R&D in product 
areas at risk of attracting litigation.
9 
Nowhere is this debate more focused than in the healthcare area. According to 
Alex Azar, the general counsel of the U.S. Department of Health and Human Services, 
defensive medicine, or the practice of ordering tests or other procedures solely as a 
protection against litigation, raises healthcare costs by as much as 70 to 126 billion 
                                                 
2 See George L. Priest,“Understanding the Liability Crisis,” Liability: Perspective and Policy (1988).  
3 See W. Kip Viscusi, “The Social Costs of Punitive Damages Against Corporations in Environmental and 
Safety Torts,”  Geo. L. J. 285 (1998). P. 87.     
4 See Cass R. Sunstein, David a. Schkade, Daniel Kahneman, “Do People Want Optimal Deterrence?”  
Punitive Damages: How Juries Decide (2002) The concept of optimal deterrence applied here is that which 
is accepted in the field of law and economics.  “People appear to reject the view, widespread within 
economic analysis, that punishment should be increased beyond compensation where the probability of 
detection is low, and that compensation is adequate where the probability of detection is 100%.” 
5 See Steven Garber, “Product Liability, Punitive Damages, Business Decisions and Economic Outcomes,” 
Wis. L. Rev. (1998). P 237.  
6 See Victor E. Schwartz, Mark A. Behrens, Joseph P. Mastrosimone, “Reining in Punitive Damages “Run 
Wild”:  Proposals for Reform by Courts and Legislatures,” Brook. L. Rev. 1003 (1999). P 65. 
7 See Michael D. Green, William B. Schultz, “Tort Law Deference to FDA Regulation of Medical 
Devices,” Geo. L. J. 2119 (2000). P 88 
8 See Dan L. Burk, Barbara A. Boczar, “Biotechnology and Tort Liability:  A Strategic Industry at Risk,” 
U. Pitt. L. Rev. (1994). P. 55. 
   
9 See Steven Garber, “Liability and Patient Health,” Transcript of Conference Sponsored by AEI-Brookings 
Joint Center and Common Good, March 4, 2003.                                                                                                                                    3
dollars a year.
10  Unfortunately, the financial costs are not the entire story.  Unnecessary 
interventions can be invasive, risky, and sometimes painful.       
 
To explore further the importance of the problem of defensive medicine, a recent 
Harris poll commissioned by Common Good (a healthcare poll hereafter referred to as 
Harris HC) interviewed physicians, nurses, and hospital administrators to explore how 
the fear of litigation affects the practice of medicine and the delivery of medical care.  It 
revealed that nearly all physicians and hospital administrators feel that unnecessary or 
excessive care is very often or sometimes provided because of fear about litigation.   
Physicians indicated in the poll that fear of malpractice claims causes them (or other 
physicians) to: 
 
•  Order more tests than they would based only on professional judgment of what is 
medically needed. (91% have noticed other physicians, and 79% report they 
themselves do this due to concerns about malpractice liability.) 
•  Refer patients to specialists more often than they would, based only on their 
professional judgment of what is medically needed. (85% have noticed other 
physicians, and 74% report they themselves do this due to concerns about 
malpractice liability). 
•  Suggest invasive procedures such as biopsies to confirm diagnoses more often 
then they would, based only on their professional judgment of what is medically 
needed. (73% have noticed other physicians, and 51% report they themselves do 
this due to concerns about malpractice liability.) 
•  Avoid candid discussions of medical mistakes when they are made. (Fear of 
liability is cited by physicians and hospital administrators as the leading factor 
that discourages medical professionals from openly discussing and thinking of 
ways to reduce medical errors.)
11 
 
Most of the literature on the impact of the liability system on healthcare has 
focused on defensive medicine in the context of the delivery of care, particularly in 
relation to diagnostic and treatment procedures. There has been little attention paid to the 
impact on pharmaceuticals--prescribing, the warnings about side effects, and patient 
compliance with recommended medications. The Harris HC poll did ask about doctors 
prescribing more medications than necessary, and it found that doctors prescribe more 
medications, such as antibiotics, than they would based only on their professional 
                                                 
10 See Alex Azar, id. at 4. 
   
11 See Fear of Litigation, Harris Interactive, April 2002.                                                                                                                                      4
judgment of what is medically needed. (Some 73% have noticed other physicians, and 
41% report they themselves do this due to concerns about malpractice liability.)   
However, the poll did not ask whether doctors sometimes avoid prescribing certain 
medications that they deem appropriate for their patients because the medications have or 
could become targets of litigation. Similarly, although the literature on defensive 
medicine has focused primarily on the delivery of healthcare in doctors’ offices and in 
hospitals, little is known about the impact of liability on pharmacies and pharmacists’ 
practices.
12 
To fill this void and expand what is known about the impact of liability on 
healthcare, and on patient well being, the U.S. Chamber of Commerce commissioned a 
Harris poll of physicians, pharmacists, and patients with the objective of better 
understanding how the behaviors of individuals within these groups are affected by 
litigation involving pharmaceuticals (hereafter referred to as Harris PHRM).
13 The survey 
is based upon 250 interviews with physicians, 251 interviews with pharmacists, and 301 
interviews with patients. (The sampling error for this poll is +- 6.9% for physicians, +- 
6.2% for pharmacists and +-5.6% for patients.) To target patients who are likely to be 
currently taking medications (or needing to take medications in the future) patients 
qualified for the poll if they had been diagnosed with at least one of eight specified 
medical conditions: high cholesterol, hypertension, arthritis, depression, obesity, diabetes, 
heart disease, or stomach ulcers. The findings of that poll are discussed in this paper, and 
the entire poll, including detail about the methodology, appears as an attachment.
14 
 
The Impact of the Fear of Pharmaceutical Litigation on Physician Practices   
In most jurisdictions doctors have a duty to warn patients of side effects 
associated with a drug, and the pharmaceutical companies are relieved of this duty, when 
                                                 
12 The Harris poll commissioned by Common Good expanded the prior, almost exclusive, focus of the 
impact of fear of liability on physician practices to include hospital administrators and nurses.  For 
example, nearly half or 43% of all nurses also feel prohibited or discouraged from doing what they think is 
right for the patient because of rules or protocols set up for liability protection.    
 
13 See Pharmaceutical Liability Study Report on Findings, Harris Interactive, July 2003.  
 
   
14 See http://www.aei-brookings.org/admin/pdffiles/phpgm.pdf.                                                                                                                                      5
the pharmaceutical company has provided an adequate warning to the doctor
15. This 
“learned intermediary doctrine” first emerged in the 1960s, and is premised on several 
assumptions:  
 
•  physicians can evaluate best an individual patient’s medical needs and possible 
drug sensitivities,  
•  patients may wish to participate in the decision as to whether or not to take on the 
risks of a particular drug,  
•  a physician can provide ongoing supervision of the patient’s use of the drug, and  
•  physicians are best positioned to manage any possible side effects that do occur.   
 
The learned intermediary doctrine does not relieve the manufacturer of the duty to 
provide adequate warnings of risks associated with specific drugs it merely requires that 
an adequate warning be given to physicians who might prescribe the drug. The 
assumption is that physicians will pass on an appropriate warning to their patients.
16  
The communication of warnings, however, has been distorted and complicated by 
fears of tort liability. According to FDA Commissioner Dr. Mark McClellan, “So long as 
the product developers we work with are facing an environment in which any adverse 
outcome can result in a major lawsuit, we may get labels written for lawyers, not doctors 
and patients. Because risk management often means reducing liability risks not reducing 
patient risks, there’s pressure to make labels read like liability avoidance tools.  Instead 
they should be efficient documents for conveying risk--tools for helping doctors help 
patients.  To protect the health of the public product labels should be written with the 
patient in mind, not a jury.”
17 Three in four (74%) doctors interviewed for the Harris 
PHRM poll feel that the information contained in the patient packet insert is more 
complicated than it needs to be--and that product liability litigation plays a critical role in 
making it complicated. In fact, nine in ten (91%) physicians who think the information is 
too complicated believe that product liability is the problem.  
                                                 
15 See Bernard J. Garbutt III, Melinda e. Hofmann, “Recent Developments in Pharmaceutical Products 
Liability Law:  Failure to Warn, the Learned Intermediary Defense, and Other Issues in the New 
Millennium,” Food & Drug L.J. 269 (2003). P. 58 (Pharmaceutical companies can be sued under 
negligence or strict liability theories for product defects.) 
16 See Laurie K. Marshall, “Keeping the Duty to Warn Patients of the Risks and Side Effects of Mass- 
Marketed Prescription Drugs Where it Belongs:  With Their Physicians,” U. Dayton L. Rev. 95 (2000). P. 
26    
   
17 Mark B McClellan, MD, PhD, Commissioner, Food and Drug Administration. Speech before the 
Physician Insurers Association of America, May 24, 2003, Chicago, IL.                                                                                                                                    6
Since many patients want to participate in making critical medical decisions it is 
imperative that patients receive accurate and understandable information about the risks 
and benefits of medical options. This is particularly true for medications where it is 
almost always true that there are potential adverse side effects. The specter of liability 
practically assures that warnings will not be clearly worded in a patient-friendly way.         
Unfortunately, the malpractice litigation environment in which doctors take on 
potential liability for the drugs they prescribe and the warnings they issue is far from 
rational and predictable. The Harris PHRM poll reveals that doctors unanimously (100%) 
agree that groundless malpractice litigation, or the threat of it, is a major concern to 
doctors. Nearly all physicians (99%) are personally concerned that they may be the target 
of groundless litigation or threat of litigation. Two-thirds of doctors (67%) say that they 
are personally very concerned about groundless litigation. Empirical research gives 
legitimacy to this fear. A study of general medical malpractice claims in the state of New 
York conducted by Harvard University revealed that for every claim that is filed by a 
meritorious plaintiff there are five or six other claims that don’t involve either a 
negligence or an injury or both.
18 
Doctors believe that malpractice lawsuits against them that result from 
prescriptions they have made occur with some frequency. Two in five (40%) doctors are 
aware of other physicians who have been sued by patients who have experienced side 
effects from a prescribed drug, even thought the drug was indicated and properly 
prescribed, leading them to think this type of litigation is common practice. In fact, most 
(57%) doctors are concerned that they may be sued by a patient who experiences side-
effects from a drug they properly prescribe. 
Doctors are handicapped in their efforts to provide adequate warnings to patients 
by the failure of the courts to defer appropriately to the expertise of the Food and Drug 
Administration (FDA). Doctors are dependent upon the patient package inserts provided 
by the pharmaceutical companies and approved by the FDA. The FDA provides an expert 
and careful review of all drug labeling, and requires that all warnings must be supported 
by solid scientific evidence. As Daniel E. Troy, general counsel of the Food and Drug 
Administration, has noted: “The agency [FDA] demands scientific substantiation not only 
                                                 
   
18 See Michele Mello, “Liability and Patient Health,” conference sponsored by AEI-Brookings Joint Center, 
March 4, 2003.  The study focused on medical malpractice claims generally, not just on claims involving 
pharmaceuticals.                                                                                                                                    7
for statements concerning the drug’s clinical utility, but also for statements of precaution, 
contraindication, and warning. A statement in the labeling of a prescription drug has been 
found by FDA to represent the most current and complete scientific information.  If a 
statement has been omitted, it is generally because FDA has not found it scientifically 
substantiated or necessary to assure safe use of the drug.”
19 Yet, taken together, doctors 
don’t get clear and consistent messages from the FDA and from the courts.   
The dominance of lawsuits without negligence creates a situation of great 
uncertainty for doctors. They realize the liability system does not have clearly defined 
rules, where violating the rules means liability is incurred and compliance with the rules 
means protection from liability will be granted. Professor George Priest of Yale Law 
School has often referred to this as the “gotcha” system of liability.       
How does this fear affect physicians’ choices regarding prescribing medications?  
A sizable number of physicians (43%) have avoided prescribing a particular drug that 
was appropriate for a patient because they were aware that it might be involved in 
product liability litigation. Although most physicians do not observe this as a common 
occurrence, 28% of surveyed physicians did indicate it happened frequently or very 
frequently. This is less than one third, but the results occur in a situation where the 
number of physicians responding affirmatively should be zero. Clearly, all patients want 
their doctors to base their care on medical considerations, not legal considerations.     
Doctors also are aware that patient behavior may be influenced more by 
information coming from the liability system than by information about risks coming 
from their own doctors. Two in five (38%) doctors reported in the survey that they know 
of patients who have stopped taking a medication that was properly prescribed for them 
because the patient discovered the drug was involved in product liability litigation.   
About three in ten (29%) doctors have had patients refuse to take a drug properly 
prescribed for them because they were aware that the drug was involved in product 
liability litigation.  Despite the fact that the liability system does a poor job of keeping 
out unfounded lawsuits, some patients seem to treat the mere existence of a lawsuit as an 
indication that a drug is harmful.                 
 
                                                 
   
19 See Dan Troy, FDLI Update, Jan/Feb 2003.                                                                                                                                    8
The Impact of the Fear of Pharmaceutical Liability on Pharmacists’ Behaviors 
 
Historically, pharmacists have been on the liability hook almost solely through 
errors made in filling prescriptions: mistakes involving failure to provide the correct 
medication, the proper dose, or accurate directions for use.
20 Three theories have 
generally been relied on to relieve pharmacists of a duty to warn:   
 
1)  it would interfere with the doctor-patient relationship,  
2)  it would violate the learned intermediary doctrine, and/or  
3)  it would contradict public policy.
21    
 
Recently pharmacists as a professional group have been expanding their role well 
beyond that of prescription fulfillment to play a more active role in the healthcare 
delivery system. This new vision of “pharmaceutical care” transforms the pharmacist into 
a caregiver who provides patient education, monitoring, and adverse event reporting
22. 
Through these changes in the professional paradigm, pharmacists are creating a new 
standard of care, one that incorporates a responsibility to warn patients. As noted by 
Myhra, of Texas Tech University School of Law: 
 
Today’s pharmacy education, in contrast, is patient oriented.  Pharmacists receive 
five or more years of education and training, during which they learn, among 
other things, how to interact with patients and physicians and how to provide 
information and warnings to patients.  In short, pharmacy schools emphasize the 
necessity for pharmacists to take active roles in the provision of patient health 
care and, importantly, in the counseling of patients about prescription medications 
and potential problems such as adverse interactions and side effects.
23 
 
Most courts addressing the pharmacists’ potential duty to warn have not 
addressed this shift in the profession. However, courts in several jurisdictions have noted 
this change and in so doing have found a duty to warn. These courts have acknowledged 
the expertise of the pharmacist and the potential for improved therapeutic outcomes if 
                                                 
20 See R. Paul Asbury, “Pharmacist Liability:  The Doors of Litigation Are Opening,” Santa Clara L. Rev. 
907 (2000). P. 40 
21 See Jennifer L. Smith, “Between a Rock and a Hard Place:  The Propriety and Consequence of 
Pharmacists’ Expanding Liability and Duty to Warn,” Hous. J. Health L. & Pol’y 187 (2002). P. 2 
22 See Alison G. Myhra, “The Pharmacist’s Duty to Warn in Texas,” Rev. litig. 27 (1999). P. 18 
   
23 See id. at 60.                                                                                                                                    9
this duty is imposed.
24 To some extent the courts may also be reacting to Congressional 
requirements that pharmacists expand their role and deliver more direct care.
25  
When patients face the task of deciding whether or not to take a medication that 
has been prescribed for them, they need to balance the potential benefits of the drug 
against the risk of side effects and the seriousness of the side effects. To do this they need 
information that does not exaggerate either side of that equation. One would expect that 
this environment of expanding liability would inhibit candor by pharmacists in that it 
likely would cause them to overemphasize the risks and seriousness of the side effects.  
In fact, two in five (39%) pharmacists surveyed in the Harris PHRM poll indicated that 
they often over-emphasize the possible side effects of prescription drugs to patients. One 
in ten (10%) does this very often. Half of pharmacists (51%) believe the information 
given to patients in the patient packet insert is too complicated and that product liability 
is central to making it complex. So, patients appear to be getting overly complicated 
information in the package inserts, and then too often they get information from 
pharmacists who overemphasize the risks.  
As is the case with physicians, pharmacists reported instances when patients have 
stopped taking medication or refused medication that was properly prescribed because of 
awareness the medication was the subject of litigation. Over two in five (44%) 
pharmacists report that some of their patients have stopped taking medication that was 
properly prescribed for them because they found out the drug might be involved in 
product liability litigation. Two in five (40%) pharmacists also report that patients have 
refused to take a properly prescribed drug because the patient knew the medication was 
involved in product liability litigation.   
 
The Impact of Pharmaceutical Liability on Patients       
 
It has already been noted that the fear of liability may have an adverse effect on 
patients in several respects: 
 
                                                 
24 See id. at 71. 
25 The Omnibus Budget Reconciliation Act of 1990 (OBRA) requires states to implement “drug use 
review’ programs to ensure that prescriptions are appropriate, medically necessary, and not likely to result 
in adverse events.  It requires, among other things, that pharmacists offer to discuss with patients, in detail, 
                                                                                                                                       10
•  The financial costs of defensive medicine are high and passed through to patients.  
•  Unnecessary tests or procedures that are not medically necessary but are ordered 
as a protection against liability impose risks and discomfort on patients. 
•  Doctors prescribe more medications than are needed, putting patients 
unnecessarily at risk of side effects.
26 
•  Patient packet inserts are more complicated than they need to be due to the 
influence of liability, interfering with the ability of patients to get meaningful 
information about risks and possible side effects.     
•  Physicians sometimes avoid prescribing appropriate medications because of 
litigation fears. 
•  Pharmacists sometimes over-emphasize the risks and seriousness of side effects 
because of liability fears.    
•  Both physicians and pharmacists report that they are aware of patients who 
refused to take a medication, or discontinued taking a medication, because of 
litigation involving the drug. 
 
Harris also went to the patients themselves to supplement this information. In the 
interest of interviewing people who were currently under medical care, the interviewees 
were randomly selected from lists of patients with at least one of eight medical problems: 
high cholesterol, hypertension, arthritis, depression, obesity, diabetes, heart disease, or 
stomach ulcers. The patients were asked about their awareness of product liability 
litigation involving specific drugs. As testament to the ubiquity of trial lawyer advertising 
to solicit clients for pharmaceutical product liability actions, most patients (86%) are 
aware of advertisements run by law firms about product liability suits over a specific 
drug. One in five (21%) have seen an advertisement for litigation over a drug they were 
taking.   
Patients react to such advertisements with concern. Nearly nine in ten (86%) of 
the patients would be concerned if they saw an advertisement regarding litigation over a 
drug they were taking. Half (50%) would be very concerned. The patients were asked 
what actions they would take as a result of seeing such litigation ads. The results were as 
follows: 
•  Would call their doctor:  90% yes, 6% no, 4% not sure; 
•  Would stop taking the drug immediately:  25% yes, 44% no, 31% not sure; 
•  Would call the law firm mentioned in the ad:  19% yes, 47% no, 34% not sure. 
                                                                                                                                                 
facts about the use of medications, including “side effects, adverse effects, adverse interactions, or 
contraindications.”       
   
26 In addition, the excessive prescribing of antibiotics has contributed to a reduction in their efficacy.                                                                                                                                        11
Less than one in ten (8%) have ever had to do any of these. This is inconsistent 
with the findings discussed above: one in five has seen a litigation-related ad for a drug 
he/she was actually taking, nine in ten would react to such an ad with concern, and nine 
in ten would call their doctors. Since the people who were interviewed were in the 
continuing care of their doctors, it is possible that the need to call their doctors was 
obviated by regular visits at which time the medication could be discussed.   
The majority of patients (69%) also express concern if a packet insert warns of 
possible serious side effects, with one in five (20%) patients not taking a drug prescribed 
by his/her doctor as a result of reading information about possible serious sides effects 
provided by the patient packet insert. This information about patient noncompliance 
underscores the need to have packet inserts communicate side effects and risks in a way 
that is clear and meaningful to patients, not in complicated legalese as is often the case.    
Although patients would be alarmed by news that a drug they were taking was the 
object of litigation, patient responses to questions about whether or not such litigation is 
likely to be meritorious reveal a cynicism about the litigation. Most patients (72%) 
believe that it is common for law firms to file product liability lawsuits against drug 
companies when only a small number of people have experienced side effects from a 
drug. Two in five (41%) think it is very common for law firms to do this.  Although few 
patients (27%) say they would join a lawsuit over a drug if they had not experienced side 
effects, the majority (86%) thinks that it is common for other people to join these 
lawsuits. Two in five (43%) believe it is very common for people to join a lawsuit over a 
drug they were taking, even if they had not experienced any side effects from the drug. 
Patients have a striking awareness of the possible overdeterrence effect of product 
liability litigation. The majority of patients (71%) feel that product liability litigation, or 
the fear of litigation, has likely caused pharmaceutical companies to avoid research in 
certain product areas. Over a third (35%) say it is very likely that companies have 
avoided research because they fear groundless product liability litigation.  Four in five 
(80%) patients are concerned that groundless product liability litigation prevents 
pharmaceutical companies from developing new and beneficial drugs. Nearly half (44%) 
say they are very concerned this may be occurring. 
 
                                                                                                                                       12
There is independent evidence that their concerns are founded in fact. Below are 
some examples:   
 
A Conference Board survey of corporate CEOs, across many industries including 
pharmaceuticals, revealed that 36% had been prompted to discontinue products because 
of litigation, and 30% had decided against introducing a new product because of litigation 
concerns.
27  
In the early 1990s liability against vaccine manufacturers drove many from the 
market.  For some vaccines, only a single supplier existed in 1994.  For one manufacturer 
a single punitive damage claim totaled more than 200 times the annual revenue generated 
by the vaccine.
28  
Steven Garber of RAND has developed a simulation model based on how R&D 
decisions get made in pharmaceutical companies. It’s based on an investment model that 
looks at future profit flows and discounts them to present value, factoring in product 
liability risks above and beyond typical risks for a typical product. Garber uses the model 
to illustrate how incremental increases in the discount rate caused by projected increases 
in product liability risks can significantly affect a company’s R&D decisions such as 
whether to initiate clinical trials. He notes that “product liability risks can have a very 
real, a very very large effect on incentives to innovate.”
29  
Finally, the likely impact of significant tort liability in the biotechnology industry 
is particularly poignant, in light of the role that industry plays in pharmaceutical 
innovation. To quote Burk, George Mason Law School, and Boczar, McCutchen, Doyle, 
Brown, and Enersen: 
 
The possibility of overdeterrence in the biotechnology industry is heightened by 
additional factors related to the structure of the industry.  Dedicated 
biotechnology companies tend to be small, entrepreneurial, and focused on a 
single product.  Any shadow on a small company’s single product is likely to 
portend the end of that company.  This is what occurred, for example, in the case 
of Cetus Corporation.  Although Cetus was considered a large and relatively 
strong DBC, postponement of FDA approval for its flagship product, 
                                                 
27 See Schwartz, supra note 5, at 1010. 
28 See Gregory C. Jackson, M.D. “Pharmaceutical Product Liability May Be Hazardous to Your Health:  A 
No-Fault Alternative to Concurrent Regulation,” Am. U. L. Rev. 199 (1992). P. 42.  In response to this 
crisis the Congress passed into law a federally administered compensation system for vaccine claimants.  
   
29 See Garber supra note 8 at 14.                                                                                                                                       13
Interleukein-2, contributed to the company’s dissolution.  A court injunction or 
major damage award could lead to the same result for many biotech companies, 
and even a single such incident could well discourage the capital investments that 






Using a Harris poll of doctors, pharmacists, and patients to inquire about the 
impact of liability on pharmaceutical prescribing, warning, and compliance adds force to 
the existing evidence that the tort liability system creates overdeterrent effects. The 
impact on patients may be significant: doctors may avoid the best prescription because of 
liability fears; pharmacists may overemphasize the risks and frighten patients into not 
taking it; patients may learn of litigation involving the drug and not begin the medication 
or stop taking medication they are currently on; and pharmaceutical companies may fail 
to develop or to bring to market new medications out of fear that they will become targets 
of unfounded litigation. More research is needed to clarify how frequently this occurs and 
to what effect. It is likely that much of this overdeterrence is fueled by the 
unpredictability of the tort system, which fails to set up clear rules or standards ex ante so 
that doctors and pharmacists can assess which behaviors will expose them to liability and 
which will protect them from liability. Personal injury litigation involving a specific drug 
also frequently sends inaccurate signals to patients that a drug may have risks that go 
beyond what they were told by their physician or pharmacist. Reforms that reduce the 
unpredictability in the pharmaceutical liability system would go a long way toward 
protecting the well being of patients. 
  
 
                                                 
   
30 See Burk and Goczar supra note 7 at 830.  